PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Gastrointestinal Infections
DOI: 10.1055/s-0045-1802668
Brief Report

Gastrointestinal Tuberculosis after Vedolizumab Treatment in Inflammatory Bowel Disease: Brief Report

Vishal Sharma 
1   Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Kayal Vizhi Nagarajan 
2   Department of Gastroenterology, Hepatology and Clinical Nutrition, Aster CMI Hospital, Bengaluru, Karnataka, India
,
Parna Pathak
1   Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Rishabh Agarwal 
2   Department of Gastroenterology, Hepatology and Clinical Nutrition, Aster CMI Hospital, Bengaluru, Karnataka, India
,
Nikhil Patil
2   Department of Gastroenterology, Hepatology and Clinical Nutrition, Aster CMI Hospital, Bengaluru, Karnataka, India
,
Kim Vaiphei
3   Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Naresh Bhat
2   Department of Gastroenterology, Hepatology and Clinical Nutrition, Aster CMI Hospital, Bengaluru, Karnataka, India
› Institutsangaben Funding None.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody used to treat patients with moderate to severe inflammatory bowel disease who are refractory or intolerant to conventional therapy. It has an excellent safety profile in terms of the risk of serious or opportunistic infections primarily due to its gut-selective action. The reported risk of tuberculosis after vedolizumab treatment is considered very low. We report two cases of gastrointestinal tuberculosis in patients on vedolizumab who were tested negative for latent tuberculosis infection screening.

Keywords

microbiology - pathology - endoscopy - tuberculosis - vedolizumab

Conference Presentation

This work has not been presented at any conference or meeting.


Ethical Statement

Informed consent was taken from both the patients.


Authors' Contributions

All the authors made substantial contributions to the design of the work. K.V.N. and V.S. drafted the work and N.B. revised it critically for important intellectual content. P.P., R.A., and N.P. contributed in compiling the endoscopy images, and K.V. contributed to the pathology images.


Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.




Publikationsverlauf

Eingereicht: 07. Oktober 2024

Angenommen: 09. Januar 2025

Artikel online veröffentlicht:
06. März 2025

© 2025. Gastroinstestinal Infection Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Raine T, Bonovas S, Burisch J. et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 2022; 16 (01) 2-17
    CrossrefPubMedSuche in Google Scholar
  • 2 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 2020; 158 (05) 1450-1461
    CrossrefPubMedSuche in Google Scholar
  • 3 Colombel JF, Sands BE, Rutgeerts P. et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66 (05) 839-851
    CrossrefPubMedSuche in Google Scholar
  • 4 Loftus Jr EV, Feagan BG, Panaccione R. et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther 2020; 52 (08) 1353-1365
    CrossrefPubMedSuche in Google Scholar
  • 5 Cohen RD, Bhayat F, Blake A, Travis S. The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data. J Crohns Colitis 2020; 14 (02) 192-204
    CrossrefPubMedSuche in Google Scholar
  • 6 Scribano ML. Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24 (23) 2457-2467
    CrossrefPubMedSuche in Google Scholar
  • 7 Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of treatment for latent tuberculosis infection in patients with inflammatory bowel disease receiving biologic therapy. Inflamm Bowel Dis 2018; 24 (10) 2272-2277
    CrossrefPubMedSuche in Google Scholar
  • 8 Choi MG, Ye BD, Yang SK, Shim TS, Jo KW, Park SH. The risk of tuberculosis in patients with inflammatory bowel disease treated with vedolizumab or ustekinumab in Korea. J Korean Med Sci 2022; 37 (14) e107
    CrossrefPubMedSuche in Google Scholar
  • 9 Sartori NS, de Andrade NPB, da Silva Chakr RM. Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review. Clin Rheumatol 2020; 39 (05) 1439-1447
    CrossrefPubMedSuche in Google Scholar
  • 10 Giri S, Bhrugumalla S, Shukla A. et al. Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening. Arab J Gastroenterol 2024; Feb 21:S1687-1979(24)00013-3.
    CrossrefPubMedSuche in Google Scholar